Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy – a Randomized Double-Blind Placebo-Controlled Study

Open access
Sutinen, Jussi, Häkkinen, Anna-Maija, Westerbacka, Jukka, Seppälä-Lindroos, Anneli, Vehkavaara, Satu, Halavaara, Juha, Järvinen, Asko, Ristola, Matti, Yki-Järvinen, Hannele · 2003 · Antiviral Therapy

Abstract

Highly active antiretroviral therapy (HAART) is associated with metabolic adverse events such as insulin resistance and lipodystrophy, that is, atrophy of subcutaneous fat and accumulation of intra-abdominal fat. Currently, there is no pharmacological treatment for lipoatrophy. Glitazones, a novel class of insulin-sensitizing anti-diabetic agents, increase subcutaneous fat in patients with type 2 diabetes. There are no controlled studies of glitazones in patients with HAART-associated lipodystrophy (HAL). In this randomized, double-blind, placebo-controlled study, 30 patients with HAL received either rosiglitazone (8 mg daily) or placebo for 24 weeks. Baseline characteristics were compared to a group of 30 age-, sex- and weight-matched HIV-negative controls. At baseline, patients with HAL had 1.8-fold (P<0.001) more intra-abdominal and 2.4-fold (P<0.05) more liver fat than HIV-negative controls, who had 1.8-fold (P<0.001) more subcutaneous fat than the patients. After 24 weeks of treatment, rosiglitazone had no effect on body weight, subcutaneous or intra-abdominal fat (magnetic resonance imaging), total body fat (bioimpedance analysis), anthropometric measurements or serum leptin concentrations (a circulating marker of adipose tissue mass). However, rosiglitazone decreased % liver fat (spectroscopy) and serum insulin concentrations, and normalized liver function tests. During the first 12 weeks of rosiglitazone treatment, serum triglycerides increased from 3.5 ±0.5 to 6.5 ±2.0 mmol/l (from 310 ±44 to 575 ±177 mg/dl) (P<0.05) and serum cholestrol from 6.0 ±0.4 to 7.8 ±0.7 mmol/l (from 232 ±15 to 301 ±27 mg/dl) (P<0.01). Contrary to data in other patient groups, rosiglitazone did not increase subcutaneous fat in patients with HAL after 24 weeks of treatment. Rosiglitazone seemed to ameliorate insulin resistance judged by the decreased serum insulin concentrations and % liver fat. Rosiglitazone unexpectedly caused significant increases in serum triglyceride and cholesterol concentrations, which must be carefully monitored if glitazones are used in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/135965350300800303

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 189

Metadata

Authors
Sutinen, J., Häkkinen, A.-M., Westerbacka, J., Seppälä-Lindroos, A., Vehkavaara, S., Halavaara, J., Järvinen, A., Ristola, M., & Yki-Järvinen, H.
Venue
Antiviral Therapy
Published
2003-04
Volume
8
Issue
3
Pages
199-207
ISSN
  • 1359-6535 (ISSN-L)
  • 2040-2058
OpenAlex
W2412229990
Cited by
189
References
7
FWCI
29.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy – a Randomized Double-Blind Placebo-Controlled Study. https://app.cochat.ai/papers/10.1177/135965350300800303
The paper
Sutinen, J., Häkkinen, A.-M., Westerbacka, J., Seppälä-Lindroos, A., Vehkavaara, S., Halavaara, J., Järvinen, A., Ristola, M., & Yki-Järvinen, H. (2003). Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy – a Randomized Double-Blind Placebo-Controlled Study. Antiviral Therapy. https://doi.org/10.1177/135965350300800303

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.